The Alzheimer’s disease market is forecast to grow by $3.99B between 2021 and 2026 at a CAGR of 8.76%, according to a report from Technavio.
The market is driven by factors such as availability, research, and development of novel biomarkers, increasing awareness of Alzheimer's disease, and the strong pipeline coupled with approval of therapeutics. However, the high cost of therapeutics development might hamper the market growth.